News
NVRO
45.59
+4.02%
1.76
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Zacks · 06/23 16:16
BRIEF-Nevro Presents Clinical Data On HFX 10 kHz Therapy
reuters.com · 06/07 20:25
Clinical Data Presented at American Diabetes Association 82nd Scientific Sessions Reinforce Significant and Durable Benefits of Nevro's HFX 10 kHz Therapy
Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced  the results from data presentations at
Benzinga · 06/07 20:14
Expert Ratings for Nevro
Over the past 3 months, 6 analysts have published their opinion on Nevro (NYSE:NVRO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcom...
Benzinga · 06/07 17:12
Morgan Stanley Adjusts Price Target for Nevro to $55 From $74, Reiterates Equalweight Rating
MT Newswires · 06/07 10:10
Nevro Announces SENZA-PDN Clinical Data Presentations at the American Diabetes Association 82nd Scientific Sessions
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (R...
PR Newswire · 05/31 20:05
JMP Securities Adjusts Price Target for Nevro to $95 From $125, Keeps Market Outperform Rating
MT Newswires · 05/26 10:19
Nevro's Return On Capital Employed Overview
Benzinga Pro data, Nevro (NYSE:NVRO) reported Q1 sales of $87.84 million. Earnings fell to a loss of $34.33 million, resulting in a 13.91% decrease from last quarter.
Benzinga · 05/20 13:51
Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.
Zacks · 05/09 15:15
Where Nevro Stands With Analysts
Nevro (NYSE:NVRO) has observed the following analyst ratings within the last quarter:
Benzinga · 05/05 20:37
--Citigroup Upgrades Nevro to Buy From Neutral; Price Target is $78
MT Newswires · 05/05 07:41
--Piper Sandler Adjusts Nevro's Price Target to $64 From $65, Maintains Neutral Rating
MT Newswires · 05/05 07:03
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of 11.71% and 2.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 22:25
BRIEF-Nevro Reports First Quarter 2022 Financial Results
reuters.com · 05/04 22:18
Recap: Nevro Q1 Earnings
Nevro (NYSE:NVRO) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Nevro beat estimated earnings by 10.91%, reporting an EPS of $-0.98 versus an estimate of $-1.1.
Benzinga · 05/04 21:56
Nevro Q1 EPS $(0.98) Beats $(1.10) Estimate, Sales $87.84M Beat $86.18M Estimate
Nevro (NYSE:NVRO) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.10) by 10.91 percent. This is a 15.29 percent decrease over losses of $(0.85) per share from the same
Benzinga · 05/04 20:39
-- Earnings Flash (NVRO) NEVRO Reports Q1 Revenue $87.8M
MT Newswires · 05/04 16:50
Further weakness as Nevro (NYSE:NVRO) drops 6.8% this week, taking one-year losses to 62%
Taking the occasional loss comes part and parcel with investing on the stock market. Anyone who held Nevro Corp...
Simply Wall St. · 05/04 13:03
Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 04/27 19:03
Truist Securities Assumes Nevro With Hold Rating, $80 Price Target
MT Newswires · 04/13 08:27
More
Webull provides a variety of real-time NVRO stock news. You can receive the latest news about Nevro Corp through multiple platforms. This information may help you make smarter investment decisions.
About NVRO
Nevro Corp. is a global medical device company that provides solutions for the treatment of chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform. Its Senza System, Senza II System, and the Senza Omnia System are the SCS systems that delivers Nevro's 10 kilohertz (kHz) therapy. The Senza system is focused on creating traditional low frequency electrical impulses and its HF10 therapy, which allows for pain relief without paresthesia. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. The HF10 therapy delivers waveforms at 10,000 Hertz (Hz) pulse rate with a statistically driven and clinically verified programming algorithm.